Twist Bioscience (TWST) Reports Q2 2026 Financial Results
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowTwist Bioscience Corporation (TWST) reported its financial results for Q2 2026. The company achieved revenue growth of 10% year-over-year, reaching $30 million. The gross profit margin for the quarter was reported at 65%. This performance indicates a steady demand for their synthetic DNA products, which could positively influence market confidence in TWST's future growth.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Related News
Earnings
DB Growth Momentum Targets for 2028 Gain Traction
Sep 25
Earnings
Abeona Therapeutics stock Buy rating maintained by H.C. Wainwright
Sep 25
Earnings
Ultragenyx Stock Rating Reiterated by H.C. Wainwright on FDA Approval
Sep 25
Earnings
Surrozen Stock Target Raised on Wnt Pathway Validation Insight
Sep 25